Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 May;2(3):93-8.
doi: 10.1111/j.1750-2659.2008.00039.x.

Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine

Christopher Burrell  1 , Robert Booy, Nicholas Wood, Anne-Marie Egan, David Taverner, Ken Williams, Winston Liauw, Alan Moskwa, Stephanie Pepin-Covatta, Melanie Saville
Affiliations
Clinical Trial

Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine

Christopher Burrell et al. Influenza Other Respir Viruses. 2008 May.

Abstract

Background: The 2005 southern hemisphere formulation of the inactivated split-virion influenza vaccine Vaxigrip unintentionally contained a lower concentration of haemagglutinin (HA) than European Pharmacopoeia (EP) and WHO specifications for one of the three strains.

Objectives: To evaluate the immunogenicity of the 2005 southern hemisphere formulation of an influenza vaccine containing 9 microg/dose of HA for A/Wellington/1/2004(H3N2) strain, and 15 microg/dose for each of the A/New Caledonia/20/99(H1N1) strain and B/Shanghai/361/2002-like strains.

Patients/methods: In an open, non-controlled multicentre clinical trial, 75 healthy adults (18-59 years) and 65 healthy older adults (> or =60 years) were vaccinated once. Serum samples were obtained on D0 and 21 for haemagglutination inhibition (HAI) antibody titration.

Results: A high proportion of adults (64%) and elderly (68%) were already seroprotected (HAI titre of > or =40) against A/Wellington/1/2004(H3N2) before vaccination, probably due to high circulation of an antigenically similar H3N2 strain and a high 2004 vaccination rate. By D21, seroprotection rates against H3N2 attained 93.8% and 96.0% in adults and elderly respectively. The other two immunogenicity criteria for annual licensure of influenza vaccines in Europe were also met in both age groups for the H3N2 strain, and also for the H1N1 and B strains.

Conclusions: These results enabled the 2005 southern hemisphere vaccine to be used in expectation that it would provide satisfactory protection against influenza, despite the reduced H3N2 antigen content.

PubMed Disclaimer

References

    1. Nicholson KG, Wood JM, Zambon M. Influenza [review]. Lancet 2003; 362:1733–1745. - PMC - PubMed
    1. Izurieta HS, Thompson WW, Kramarz P et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342:232–239. - PubMed
    1. Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 1999; 17(Suppl. 3):S81–S87. - PubMed
    1. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2216–2226. - PubMed
    1. Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalization and death. JAMA 1980; 244:2547–2549. - PubMed

Publication types